Sanofi, a global healthcare company, is to invest €40 million ($42.3 million) into its Lyon Gerland biomanufacturing site in France.

As part of this investment, €25 million (approximately $26.4 million) will fund the production and development of the second generation of its polyclonal antibody. In addition, an investment of more than €15 million (approximately $15.8 million) is planned to internalise and localise the production of monoclonal antibodies in France for the treatment of type 1 diabetes at the pre-clinical and clinical stages of the disease.

The development of the bioproduction area will begin at the start of 2025, with the first batches to be produced at the end of 2025 and will available for marketing from 2027.